Institute of Endemic Diseases, Medical Campus, University of Khartoum, Khartoum, Sudan.
Faculty of Medicine, Medical Campus, University of Khartoum, Khartoum, Sudan.
Trans R Soc Trop Med Hyg. 2019 Jul 1;113(7):428-430. doi: 10.1093/trstmh/trz027.
The emergence of resistant parasites to artemisinin poses a threat to malaria treatment. The study aimed to investigate K13 gene mutations in Plasmodium falciparum artesunate (AS)/sulfadoxine-pyrimethamine (SP) efficacy study in Sudan.
A total of 31 (14 failures and 17 adequate clinical and parasitological response [ACPR]) pretreatment dried blood samples from patients with uncomplicated P. falciparum malaria treated with AS/SP were examined. Nested polymerase chain reaction (PCR) and DNA sequencing of the K13 gene was performed.
PCR products were obtained from 30 (96.8%) samples and sequencing was successful in 28 (90.3%). No mutation of the K13 gene was recorded in the treatment failure group. A single mutation (C>T; A621V) in one ACPR patient sample was detected.
There is no evidence of K13 mutation among AS/SP treatment failure patients. A single mutation of the K13 gene not linked to treatment failure has been detected.
对青蒿素的抗药性寄生虫的出现对疟疾治疗构成了威胁。本研究旨在调查苏丹青蒿琥酯（AS）/磺胺多辛-乙胺嘧啶（SP）疗效研究中恶性疟原虫 K13 基因突变情况。
共检测了 31 例（14 例治疗失败和 17 例充分的临床和寄生虫学反应[ACPR]）用 AS/SP 治疗的无并发症恶性疟原虫疟疾患者的治疗前干血样。对 K13 基因进行巢式聚合酶链反应（PCR）和 DNA 测序。
从 30 个（96.8%）样本中获得了 PCR 产物，28 个（90.3%）样本测序成功。在治疗失败组中未记录到 K13 基因的突变。在 1 例 ACPR 患者样本中检测到一个单一突变（C>T；A621V）。
AS/SP 治疗失败患者中没有 K13 突变的证据。已检测到与治疗失败无关的 K13 基因突变。
